Mathieu Simon

Mathieu Simon

Director/Board Member at IDORSIA LTD

Net worth: 543 345 $ as of 31/05/2026

70 year
Health Technology
Commercial Services
Consumer Services

Profile

Dr. Mathieu Simon is a Chairman at Epsilen Bio SRL, a Chairman at Idorsia Ltd., an Independent Director at Asarina Pharma AB, an Independent Director at Vaximm AG, a Chairman at Idorsia Pharmaceuticals Ltd., a Chief Executive Officer at Cellectis Therapeutics and an Independent Director at LNC Therapeutics SA. He is on the Board of Directors at Lysogene SA, Asarina Pharma AB, Affimed NV, Affimed GmbH, Vaximm AG, Messier Maris & Associés SCA and LNC Therapeutics SA. Dr. Simon was previously employed as an EVP, Chief Operating & Medical Officer by Cellectis SA, a Vice President-Marketing & Medical Affairs by Wyeth Pharmaceuticals LLC, a Group VP-Marketing & Clinical Affairs by Wyeth-Ayerst International, Inc., a Senior Vice President-Global Operations by Pierre Fabre Médicament SAS, a Managing Director & Head-Global Pharma by Pierre Fabre SA, and a Chairman & Chief Executive Officer by Takara Bio Europe AB. He also served on the board at Alliance for Regenerative Medicine, Ectycell SASU and Farmindustria.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
31/12/2024 95,061 ( 0.04% ) 543 345 $ 31/05/2026

Mathieu Simon active positions

CompaniesPositionStart
IDORSIA LTD Director/Board Member 13/06/2024
Chairman -
Chairman 13/05/2020
Director/Board Member -
Chairman 15/06/2020
Director/Board Member 01/01/2018

Former positions of Mathieu Simon

CompaniesPositionEnd
AFFIMED N.V. Director/Board Member 26/06/2024
CELLECTIS S.A. Chief Tech/Sci/R&D Officer 14/03/2018
Cellectis Therapeutics
Chief Executive Officer 01/02/2014
░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░ ░░░░░░ ░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
See the detail of Mathieu Simon's experience

Training of Mathieu Simon

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

32

1st degree connections

22

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies22

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Commercial Services

Commercial Services

Health Technology

Health Services

Finance

Health Technology

Health Technology

Wyeth-Ayerst International LLC

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Cellectis Therapeutics

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!